Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology
+$0.03 today
- Market cap
- $103.50M
- Beta
- 0.42
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.19
Volume 1.28M
Average 0.21M
TLSA Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Operating Margin history
Percent of revenue · from the income statement
No Operating Margin data reported for this period type.
Operating Margin vs competitors
How TLSA compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -40.5% | +24.7 pp | +32.2 pp | |
| LTM Mar 2026 | -277.0% | +250.6 pp | — | |
WHWKWhitehawk Therapeutics Inc | FY2025 | -1601.1% | -1341.5 pp | -1189.2 pp |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
EXOZeXoZymes, Inc. | FY2025 | — | — | — |
| Peer median (excluding TLSA) | -277.0% | +24.7 pp | -578.5 pp | |
Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 234K |
| Gross Profit | 0 | 0 | 0 | 0 | (234K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 17.82M | 15.92M | 10.25M | 5.23M | 10.28M |
| Selling, General & Admin | 1.15M | 4.76M | 8.26M | 10.28M | 10.77M |
| Operating Expenses | 36.93M | 17.93M | 22.73M | 15.79M | 21.05M |
| Depreciation & Amortization | 190.2K | 62.68K | 121.34K | 124K | 234K |
| EBITDA | (35.53M) | (18.85M) | (21.66M) | (16.62M) | (21.05M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.93M) | (17.93M) | (22.73M) | (15.79M) | (21.28M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.46M | 814K | 19K |
| Interest Expense | 237.41K | 8.6K | 12.64K | 6K | 18K |
| Other Income / Expenses | 967.18K | (996.78K) | 937.89K | (952K) | 2.85M |
| Income Before Tax | (35.96M) | (18.92M) | (21.79M) | (16.75M) | (18.43M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (4.37M) | 0 | 567.54K | (4.88M) | 0 |
| Net Income | (31.59M) | (18.92M) | (22.36M) | (11.86M) | (18.43M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.64) | (0.36) | (0.42) | (0.22) | (0.32) |
| EPS (Diluted) | (0.64) | (0.36) | (0.42) | (0.22) | (0.32) |
| Weighted Avg Shares | 48.97M | 50.76M | 50.76M | 53.34M | 59.14M |
| Weighted Avg Shares (Diluted) | 48.97M | 50.76M | 50.76M | 53.34M | 59.14M |
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.